pantoprazole has been researched along with Colorectal Neoplasms in 2 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pantoprazole (PPZ) was identified to be a TOPK inhibitor from FDA-approved drug database by structure based virtual ligand screening." | 5.43 | Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. ( Chen, P; Duan, Q; Huang, G; Li, H; Liu, L; Lu, T; Sun, H; Xiao, J; Zeng, X; Zhang, J; Zheng, M; Zhu, F, 2016) |
| "Pantoprazole (PPZ) was identified to be a TOPK inhibitor from FDA-approved drug database by structure based virtual ligand screening." | 1.43 | Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. ( Chen, P; Duan, Q; Huang, G; Li, H; Liu, L; Lu, T; Sun, H; Xiao, J; Zeng, X; Zhang, J; Zheng, M; Zhu, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schreiber, V | 1 |
| Kitzmueller, M | 1 |
| Poxhofer, M | 1 |
| Gintersdorfer, S | 1 |
| Neudorfer, C | 1 |
| Lichtneckert, M | 1 |
| Dittrich, C | 1 |
| Czejka, M | 1 |
| Zeng, X | 1 |
| Liu, L | 1 |
| Zheng, M | 1 |
| Sun, H | 1 |
| Xiao, J | 1 |
| Lu, T | 1 |
| Huang, G | 1 |
| Chen, P | 1 |
| Zhang, J | 1 |
| Zhu, F | 1 |
| Li, H | 1 |
| Duan, Q | 1 |
2 other studies available for pantoprazole and Colorectal Neoplasms
| Article | Year |
|---|---|
Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antineoplastic Agents; Cell Proliferation; Colorec | 2016 |